TRACON Pharmaceuticals has reported positive results from the National Cancer Institute (NCI) Phase Ib/II clinical trial of TRC105 and Nexavar (sorafenib) to treat patients with hepatocellular cancer (HCC).

TRC105 is a clinical stage antibody to endoglin protein, which is found to be over-expressed on proliferating endothelial cells and is required for formation of new blood vessels.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results showed an overall response rate (ORR) of 25% measured by the Response Evaluation Criteria in Solid Tumours (RECIST) and a median overall survival of 15.5 months, both of which were greater than that observed for Nexavar alone in prior trials.

A total of 26 advanced HCC patients were enrolled in the Phase Ib/II trial and were administered TRC105 with either 3, 6, 10mg/kg or 15mg/kg every two weeks in combination with the standard dose of 400mg twice-daily Nexavar.

All responses occurred at the two highest dose levels of TRC105, with the ORR being 33%, and the median progression-free survival (PFS) being 3.8 months.

"The final data from the NCI study of TRC105 and Nexavar in HCC published today reinforce the encouraging preliminary data presented previously at ASCO."

Furthermore, the combination was well-tolerated at the recommended single agent doses of both drugs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TRACON Pharmaceuticals president and CEO Charles Theuer said: “The final data from the NCI study of TRC105 and Nexavar in HCC published today reinforce the encouraging preliminary data presented previously at ASCO.

“Collectively, these data suggest that the combination of TRC105 and Nexavar is active in patients with HCC and support the advancement of this combination into further clinical studies.”

TRC105 is being investigated in a Phase III and several Phase II trials sponsored by TRACON or the NCI to treat solid tumours in combination with VEGF inhibitors.

TRACON is currently funding another Phase I/II multi-centre trial of the combination to confirm the NCI-reported activity.

NCI is responsible for enrolment into this trial and the results are expected to be available early next year.